-
-
Sunday, March 25 ,2007
-
Hilton New Orleans Riverside Two Poydras Street, New Orleans, Louisiana
-
Grand Ballroom A
-
5:30 AM—6:00AM Registration and Breakfast
-
6:00 AM—7:00AM General Session
-
-
Agenda
-
5:30 AM Registration and Breakfast
-
6:00 AM Program introduction
-
6:05 AM Type 2 Diabetes:The Growing Epidemic Peter Reaven,MD
-
(Director the Vascular Disease Prevention Program Brigham & Women’s Hospital Associate Professor of Medicine Harvard Medical School,Boston,Massachusetts)
-
Type 2 Diabetes and CVD Considerations Jorge Plutzky,MD
-
（Associate Professor of Clinical Medicine University of Arizona College of Medicine Phoenix, Arizona）
-
6:45 AM Question and Anwer Session
-
7:00 AM Program Adjourns
-
-
Program Overview
-
One out of four patients with type 2 diabetes in the United States dies of a cardiovascular event. This statistic, along with the epidemic of diabetes ,has created an opportunity for cardiologists to intervene in the management of patients with type 2 diabetes. This program will look at the latest data published over the last 18 months that have presented information to minimize the risk of a cardiovascular event by controlling glucose levels for the at-risk patient. A cardiologist and endocrinologist will discuss this new data and how these outcomes can be applied in order for the cardiologist to create effective management strategies for patients at risk.
-
-
Learning Objective
-
At the conclusion of this activity, participants should be able to:
-
l Describe how pharmacologic interventions may prevent or delay disease progression by improving insulin sensitivity and β–cell function
-
l Explain how therapeutic approaches that control vascular inflammation in susceptible patients may decrease cardiovascular events
-
-
Target Audience
-
This symposium has been developed to meet the educational needs of cardiologists who are interested in raising the levels of care for their patients with type 2 diabetes.
-
-
Faculty Disclosure
-
In accordance with the disclosure policies of SUNY Upstate Medical University and to conform with the ACCME and US Food and Drug Administration guidelines, all faculty are required to disclose to the activity participants 1) the existence of any financial interest or other relationships with the manufacturers of any commercial products or providers of commercial services that relate to the content of theirpresentation/material, or the commercial contributors of this activity that could be perceived as a real or apparent conflict of interest; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a producty device not yet approved.
-
Faculty disclosures will be available during the activity
-
-
Accreditation
-
This cativity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of SUNY Upstate Medical University and ProCom. SUNY Upstate Medical University is accredited by the ACCME to provide continuing medical education for physicians.
-
-
Credit Designation
-
SUNY Upstate Medical University designates this educational for a maximum of 1.0 AMA PRA Category 1 CreditsTM， Physicians should only claim credit commensu